Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the appointment of Mary-Elizabeth Gifford as chief of global impact.
Prior to joining Clearmind, Gifford served as chief of global impact at Psyence BioMed, a Nasdaq-listed biopharmaceutical company focused on nature-derived psychedelic medicine.
In a statement, Dr. Adi Zuloff-Shani, PhD, CEO of Clearmind, commented, “We are thrilled to welcome Mary-Elizabeth Gifford to Clearmind Medicine. Her unparalleled expertise in psychedelic policies and regulatory landscapes, and longstanding collaborations with leading government officials, policy makers and investors oriented to this space, will be instrumental in advancing our US partnerships and positioning Clearmind as a leader in ethical, patient-centered psychedelic therapeutics.”
